Southern Archipelago (A33) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
11 Nov, 2026Executive summary
9M2026 revenue fell 26% YoY to S$2.34m; net loss narrowed to S$596k from S$722k.
A material going-concern uncertainty remains amid S$6.36m of net current liabilities and S$758k of net liabilities at period-end.
Financial highlights
Q3 revenue was S$859k, down 9% YoY; net loss was S$134k versus S$156k.
9M loss before tax was S$401k versus S$327k; income tax expense fell to S$195k from S$395k.
9M other gains rose to S$683k from S$97k, largely reflecting the prior-period S$828k dormant-subsidiary liquidation loss and current-period currency gains.
9M operating cash flow used S$316k versus S$576k generated; financing generated S$505k, and cash ended at S$457k.
Outlook and guidance
Sterilisation is expected to generate positive operating cash flow over the next 12 months following completed capacity expansion.
Management is exploring fundraising and capital-structure options; a substantial shareholder indicated continued financial support for at least 12 months from the statement date.
Customer acquisition continues, though take-up of expanded capacity has been slower than anticipated.
Latest events from Southern Archipelago
- Revenue and net profit improved, but liquidity and diversification remain key challenges.A33
H2 2023 - A return to modest profit meets weaker revenue and widening working-capital pressure.A33
H1 2024 - Sterilisation expansion continued as lower revenue, a net loss and tight liquidity shaped FY2024.A33
H2 2024 - Sterilisation growth plans amid a S$566k loss, negative working capital and covenant risk.A33
H1 2025 - Revenue fell 17.8%; upgraded capacity meets a strained balance sheet and recovery test.A33
H2 2025 - Revenue fell 47% amid Indonesian headwinds, with liquidity and covenant risks still acute.A33
Q1 2026 - Sterilisation rebounded in 2Q, but liquidity pressure and a loan covenant breach persist.A33
H1 2026